Effect of Dapagliflozin on N-Terminal Prohormone of Brain Natriuretic Peptide and some Biochemical Parameters in Patients with Heart Failure | ||||
| Journal of Bioscience and Applied Research | ||||
| Articles in Press, Accepted Manuscript, Available Online from 05 August 2025 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jbaar.2025.374702.1184 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Saleh Netish Khashlok; Alyaa Majid  
| ||||
| Department of Chemistry, College of Science, University of Thi-Qar, Thi-Qar, 64001, Iraq. | ||||
| Abstract | ||||
| The cardiovascular system benefits from dapagliflozin, a member of the class of hypoglycemia medications known as SGLT-2 inhibitors. The purpose of the current research is comparing the levels of NT-Pro BNP, creatinine, urea, K, and Na in patients to those in healthy individuals (controls). There were 150 participants in the research: 100 patients with Type 2 Diabetes Mellitus (T2DM) and heart failure (HF) and 50 controls. Based on age, the patients are split into two groups (40-70). Whereas the second group (B) just received lasix, the first group (A) received both lasix and dapagliflozin. Compared with the controls group, group B's serum concentration of NT-ProBNP, creatinine, and urea increased significantly (p ≤ 0.050). Compared to controls, group B had a significant drop in serum Na concentration (p ≤ 0.05). Serum concentrations of NT-Pro BNP, Creatinine, Urea, and Na in group B are not significantly different from the ones in group A at the time of admission. When compared to group A, group B exhibits significant differences in serum K concentration. Serum concentrations of NT-ProBNP, Creatinine, Urea, Potassium, and Sodium do not differ significantly between groups B and A at 7 days, according to the data. Additionally, in comparison with the day of baseline, the concentration of serum NT-pro-BNP in patients in groups B and A was significantly lower on the seventh day of baseline. Dapagliflozin works well to lower NT-Pro BNP levels and alleviate the symptoms of HF. It improves cardiac function, quality of life, and reduces fluid retention | ||||
| Keywords | ||||
| Lasix; Dapagliflozin; Kidney Function Tests; NT-Pro BNP; Heart Failure | ||||
|
Statistics Article View: 36 |
||||
